Erythropoietin and the heart: Physiological effects and the therapeutic perspective. Fabian Sanchis-Gomar, José Luis Garcia-Gimenez, Helios Pareja-Galeano, Marco Romagnoli, Carme Perez-Quilis, Giuseppe Lippi; International Journal of Cardiology, Available online 18 December 2013, http://dx.doi.org/10.1016/j.ijcard.2013.12.011
Keywords: Myocardial infarction; cardioprotection; remodelling; EpoR; angiogenesis; apoptosis; inflammation; pleiotropic actions; Friedreich’s ataxia
If rhEpo or its analogues improve(s) the muscle and mitochondrial function it would help improve the cardiac function. However, none of these studies and clinical trials mentioned the long-term effect of rhEpo on the heart of FRDA. Thus, an effort designing a clinical trial involving treatments a long term in FRDA patients are strongly recommended.
Thursday, December 19, 2013
Subscribe to:
Posts (Atom)
